» Articles » PMID: 23533029

Expanding Roles for CD4 T Cells and Their Subpopulations in Tumor Immunity and Therapy

Overview
Journal Front Oncol
Specialty Oncology
Date 2013 Mar 28
PMID 23533029
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

The importance of CD4 T cells in orchestrating the immune system and their role in inducing effective T cell-mediated therapies for the treatment of patients with select established malignancies are undisputable. Through a complex and balanced array of direct and indirect mechanisms of cellular activation and regulation, this functionally diverse family of lymphocytes can potentially promote tumor eradication, long-term tumor immunity, and aid in establishing and/or rebalancing immune cell homeostasis through interaction with other immune cell populations within the highly dynamic tumor environment. However, recent studies have uncovered additional functions and roles for CD4 T cells, some of which are independent of other lymphocytes, that can not only influence and contribute to tumor immunity but paradoxically promote tumor growth and progression. Here, we review the recent advances in our understanding of the various CD4 T cell lineages and their signature cytokines in disease progression and/or regression. We discuss their direct and indirect mechanistic interplay among themselves and with other responding cells of the antitumor response, their potential roles and abilities for "plasticity" and memory cell generation within the hostile tumor environment, and their potentials in cancer treatment and immunotherapy.

Citing Articles

New T-lymphocyte subpopulations and their characteristics: Challenges to the classical division of lymphocyte function.

Lewandowski F, Niedzwiedzka-Rystwej P Cent Eur J Immunol. 2024; 49(3):308-314.

PMID: 39720272 PMC: 11664807. DOI: 10.5114/ceji.2024.144071.


Aiolos promotes CXCR3 expression on Th1 cells via positive regulation of IFN-γ/STAT1 signaling.

Leonard M, Jones D, Read K, Pokhrel S, Tuazon J, Warren R JCI Insight. 2024; 10(1.

PMID: 39560988 PMC: 11721307. DOI: 10.1172/jci.insight.180287.


Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies?.

Anvar M, Rashidan K, Arsam N, Rasouli-Saravani A, Yadegari H, Ahmadi A Cancer Cell Int. 2024; 24(1):355.

PMID: 39465401 PMC: 11514949. DOI: 10.1186/s12935-024-03525-9.


Evaluation of the Role of Tumor-Infiltrating Lymphocytes and CD8 Cytotoxic Lymphocytes in the Survival of Patients with Breast Cancer.

Shojaei S, Aznab M, Rahimi A, Ahmadi S, Eslampia K, Golpazir A Int J Hematol Oncol Stem Cell Res. 2023; 17(1):9-17.

PMID: 37638284 PMC: 10448926. DOI: 10.18502/ijhoscr.v17i1.11708.


T cells in health and disease.

Sun L, Su Y, Jiao A, Wang X, Zhang B Signal Transduct Target Ther. 2023; 8(1):235.

PMID: 37332039 PMC: 10277291. DOI: 10.1038/s41392-023-01471-y.


References
1.
Kloke O, Wandl U, Opalka B, Moritz T, Franz T, Becher R . A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia. Eur J Haematol. 1992; 48(2):93-8. DOI: 10.1111/j.1600-0609.1992.tb00572.x. View

2.
Giovarelli M, Musiani P, Modesti A, Dellabona P, Casorati G, Allione A . Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol. 1995; 155(6):3112-23. View

3.
Miyara M, Sakaguchi S . Human FoxP3(+)CD4(+) regulatory T cells: their knowns and unknowns. Immunol Cell Biol. 2011; 89(3):346-51. DOI: 10.1038/icb.2010.137. View

4.
Oldenhove G, Bouladoux N, Wohlfert E, Hall J, Chou D, Dos Santos L . Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity. 2009; 31(5):772-86. PMC: 2814877. DOI: 10.1016/j.immuni.2009.10.001. View

5.
Stuller K, Flano E . CD4 T cells mediate killing during persistent gammaherpesvirus 68 infection. J Virol. 2009; 83(9):4700-3. PMC: 2668489. DOI: 10.1128/JVI.02240-08. View